NCT06554626View on ClinicalTrials.gov

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Precursor B-Cell Lymphoblastic Leukemia
Interventions
DRUG

Dexamethasone

Glucocorticoids

DRUG

Blinatumomab

Bi-specific anti CD19/CD3 antibody

DRUG

Venetoclax

BCL-2 inhibotor

DRUG

Inotuzumab ozogamicin

a humanized monoclonal antibody-drug conjugate targeting CD22

DRUG

Methotrexate

antifolate antineoplastic drug

DRUG

Pegaspargase

antitumor drug

DRUG

Cytarabine

Pyrimidine, antimetabolites

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER